Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Adrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Speaking at the 5th Bruges European Business Conference, van den Hoven maintained that the move would be in the interest of creating a pro-competitive pharmaceutical market in the EU and fostering sustainable competition.
He underlined the crucial role for Europe as a strong EU pharmaceutical export base, to be achieved through regulatory convergence with key trade partners and regulatory approximation in the EU with developing and emerging countries.
The Bruges conference was hosted by the College of Europe and included representatives from the European institutions, national governments and academia, and business leaders from all industrial sectors. Speakers included Dr. Wolfgang Schauble, German Minister of Finance and Prof. Mario Monti, former European Commissioner and Italian Prime Minister.
This entry was posted in
Europe
,
Events
,
Global
,
Regulatory
and tagged
Bruges European Business Conference
,
EGA
,
EU
,
European Generics Association
,
generics
. Bookmark the
permalink
. Trackbacks are closed, but you can
post a comment
.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.